Phytera And Tsumura Initiate Three-Year Collaboration

4 August 1996

- Phytera has entered a three-year R&D collaboration with Tsumura of Japan, for the discovery of novel small molecules for the treatment of rheumatoid arthritis and allergies. Tsumura is to make research and milestone payments to Phytera, and will co-own any products derived from the joint venture. Tsumura will receive exclusive worldwide rights, with the exception of North America, where Phytera will retain exclusive rights.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight